Cardiac Amyloidosis: See if Intracardiac Thrombi are Common on CT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Cardiac amyloidosis can cause heart failure and rhythm problems, and patients are at higher risk of stroke due to clots in the heart. This interventional study uses a contrast-enhanced cardiac CT scan to identify intracardiac thrombi in eligible adults with confirmed cardiac amyloidosis. Participants must have recent cardiology contact at Dijon University Hospital and meet safety criteria, including adequate kidney function and no contrast allergies. The trial is conducted at Chu Dijon Bourogne in Dijon, France, led by Centre Hospitalier Universitaire Dijon. Results may inform risk stratification and imaging approaches in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals with a diagnosis of cardiac amyloidosis (AL diagnosed by echocardiography and/or MRI combined with histological evidence; or ATTR diagnosed in the presence of typical cardiac abnormalities on echocardiography and/or MRI with cardiac hyperintensity)
* Individuals who have had at least one consultation related to their cardiac amyloidosis at the Dijon University Hospital during the year prior to enrollment
* Adults

Exclusion Criteria:

* Individuals with an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m²
* Anyone with a known allergy to iodinated contrast agents
* Overt thyrotoxicosis
* Uncontrolled asthma
* Individuals with a known history of cardiac thrombus
* Individuals with a history of percutaneous or surgical closure of the left atrial appendage
* Individuals not enrolled in or not eligible for a social security program
* Individuals under legal guardianship
* Individuals under conservatorship
* Pregnant or breastfeeding women

Where it's running

• Chu Dijon Bourogne
  Dijon, France Recruiting

Study contacts

• Study coordinator: Benjamin FERRAND
• Email: benjamin.ferrand@chu-dijon.fr
• Phone: 03.80.29.35.36

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liver and Coagulation Markers in ATTR Cardiac Amyloidosis

  This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.

  Recruiting University of Messina · Messina, Sicily · NCT07766135

• Higher pacemaker rate for people with cardiac amyloidosis

  This study will see if temporarily increasing the pacemaker rate improves heart-failure symptoms and exercise tolerance in adults with cardiac amyloidosis who already have pacemakers.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07583823

• Using [64Cu]FBP8 PET/MR to find intracardiac blood clots in cardiac amyloidosis

  We'll test whether a [64Cu]FBP8 PET/MR scan can find blood clots inside the heart of people with cardiac amyloidosis who have atrial fibrillation or atrial flutter.

  Recruiting Phase 3 Brigham and Women's Hospital · Boston, Massachusetts · NCT07560306

• Chest pain screening for hidden cardiac amyloidosis

  We will test whether men over 65 who have chest pain but no coronary artery disease might have hidden cardiac amyloidosis using blood and urine tests, ECG and echocardiography, bone scintigraphy, and sometimes a heart biopsy.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT07435168

• Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies

  This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07336394

• Deep learning to analyze and track echocardiograms

  This project will test AI tools that help clinicians read echocardiograms and flag adults who may have genetic cardiomyopathy, ischemic heart disease, or cardiac amyloidosis to see if interpretation improves and diagnoses happen faster.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07308704

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.